ImmunoGenetix Therapeutics, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.  DNA immunotherapies offer a promising approach to reducing the dependency on anti-HIV drug cocktails and diminishing the emergence of drug-resistant HIV strains.  They are relatively inexpensive to produce, readily scaled up, and stable at ambient temperatures.

GenePro™ (∆4SHIVku2), the Company’s lead product candidate incorporates a proprietary DNA construct that yields high levels of gene expression and non-infectious HIV protein production, and induces a robust antibody and cellular immune response in animal models.  In preclinical efficacy studies, this immunotherapeutic candidate controlled viral replication and provided protection against a deadly AIDS causing virus in monkeys without viral protein boosts and without anti-viral therapy.

GenePro™ (∆4SHIVku2)

The ImmunoGenetix lead product candidate, GenePro™, uses a DNA composition developed through animal passaging.  This approach generates superior gene expression and subsequent non-infectious HIV protein production activity, which results in an enhanced immune response.  GenePro™ stimulates a potent cellular and antibody response that can control the replication of a deadly AIDS-causing virus in primate animal models without protein or viral vector boosts and without anti-viral therapy.